Auxilium Pharmaceuticals — Investor Presentation (October 2010)
53 slides from Auxilium Pharmaceuticals's investor presentation, Oct 15, 2010
Slide 1: October 2010
October 2010 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the pricing, time to market, size of market,
Slide 3: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates
Slide 4: XIAFLEX
AlArLEX
Slide 5: XIAFLEX – Unique Blockbuster Opportunity
XIAFLEX – Unique Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s contracture in U.S. Peyronie’s disease Phase III double-blind study enrollment anticipated to complete in 1Q11 and top-line data
Slide 6: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th
Slide 7: Treatment Options Historically Limited to Invasive Surgery or Unapproved and Ineffective
Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids
Slide 8: It Is About the Patient
It Is About the Patient Pre-XIAFLEX treatment 30 days post-single injection of XIAFLEX Immediately post-operative Intra-operative open fasciectomy Pictures courtesy of Dr. Clayton Peimer
Slide 9: Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach N=125 41%
Slide 10: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment-related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of
Slide 11: Contracture Recurrence Affects Patients
Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of 12 months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following sur
Slide 12: Two Year Recurrence Rate of 19.3% for XIAFLEX in Dupuytren's Contracture
Two Year Recurrence Rate of 19.3% for XIAFLEX in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with Re
Slide 13: Launch Update Through September 2010
Launch Update Through September 2010
Slide 14: Key Objectives for U.S. XIAFLEX Launch in 2010
Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm-changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest
Slide 15: Targeting the Eligible Patient Population Should Drive Development of the U.S. Market
Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential
Slide 16: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini
Slide 17: Unique Sales Cycle for Targeted Physicians
Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE
Slide 18: Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate
Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling – weeks from
Slide 19: Reimbursement Processes Are New to Target Physicians
Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use effective as of July 1, 2010 • CMS has recommended a J-Code for
Slide 20: Leading Indicators Trending Positively
Leading Indicators Trending Positively - Unique sites that have ordered XIAFLEX Mar Apr May Jun Jul Aug Sep PHYSICIAN ENROLLMENTS SITES ENROLLED UNIQUE SITES ORDERING
Slide 21: Cumulative Call Center Volume
Cumulative Call Center Volume Cumulative Call Center Volume
Slide 22: Sites Continue to Move from Test Drive to Increasing Usage
Sites Continue to Move from Test Drive to Increasing Usage Number of Sites Injections per Site Mar (15 Sites) Apr (58 Sites) May (139 Sites) Jun (246 Sites) Jul (351 Sites) Aug (449 Sites) Sep (554 Sites) 1-2 Injections 3-10 Injections 11 + injections
Slide 23: ~91% of insured lives have access
~91% of insured lives have access ~91% of insured lives have access
Slide 24: Out of Pocket Costs In Line With Expectations
Out of Pocket Costs In Line With Expectations A significant portion of Medicare patients with a 20% liability have secondary insurance, which may cover a portion of this cost % Of Treatment Cost Paid by Patient 56% 4% 7% 8% 23% 2% 0% 10% 20% 30% 40% 50% 60% 0% Up to 2% 2.1-9.9% 10-19.9% 20% >20%
Slide 25: Distribution Network is Operating Smoothly
Distribution Network is Operating Smoothly Unit Sales by Channel 40% 44% 16% Speciality Pharmacy Speciality Distributor Wholesaler
Slide 26: Direct to Patient Program Launching
Direct to Patient Program Launching
Slide 27: We Believe Launch Strategy Is Sound
We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good • Usage is characterized by “test driving”, which is typical for paradigm-changing treatment • Payers willing to provide access to drug and procedures • All di
Slide 28: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence Based on literature, ~ 6M to 11M patients in U.S. have a Dupuytren’s pit, nodule or cord, but only ~ 300,000 new patients annually diagnosed in U.S. • Sustainable patient pool New patients within an agin
Slide 29: XIAFLEX Intellectual Property Position
XIAFLEX Intellectual Property Position • Highly purified collagenase product and method of manufacturing patent U.S. Pat. No. 7,811,560 issued in October 2010; expected expiry in 2028 Patent applications are under review outside of U.S. • Market Exclusivity expected in U.S. for 12 years post-approva
Slide 30: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/
Slide 31: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Bella A. Peyronie’s Disease J Sex Med 2007;4:1527–1538 Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6–23. Mulhall JP, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a popu
Slide 32: Current Surgical Options Are the Treatment of Last Resort
Current Surgical Options Are the Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated
Slide 33: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 34: Phase IIb Overall Results – Reduction of Penile Curvature and Improvement in Bother
Phase IIb Overall Results – Statistically Significant Reduction of Penile Curvature and Improvement in Peyronie’s Disease Bother (PRO Domain) with XIAFLEX P = 0.001 -29.7% -11.0% XIAFLEX N = 109 Placebo N = 36 8.1 8.1 5.5 7.4 Xiaflex Placebo P = 0.046 -32.1% -8.6% XIAFLEX N = 100 Placebo N = 34 Peni
Slide 35: Phase IIb with Modeling Results
Phase IIb with Modeling Results- Statistically Significant Effect in Both Penile Curvature and Peyronie’s Disease Bother Endpoints with XIAFLEX P < 0.001 -32.4% 2.5% XIAFLEX N = 54 Placebo N = 20 8.6 7.7 7.5 Xiaflex Placebo P = 0.004 -41.8% -2.6% XIAFLEX N = 50 Placebo N = 18 Penile Curvature Bother
Slide 36: Phase IIb Safety Profile Consistent with Previous XIAFLEX Studies
Phase IIb Safety Profile Consistent with Previous XIAFLEX Studies in Peyronie’s Disease • Well tolerated • Immunogenicity profile similar to Dupuytren’s data • Injection site bruising, edema, pain – most common • No drug related SAEs • No systemic immunologic events
Slide 37: Peyronie's Disease Phase III Development Program
Peyronie’s Disease Phase III Development Program Study Type ~ # Subjects Sites XIAFLEX: Placebo Duration AUX-CC- Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC- Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC- Open Label 12 US 6 NZ 12 EU N/A 36 Wks AUX-CC- Pharmaco
Slide 38: Phase IIb vs. Phase III Protocol Differences
Phase IIb vs. Phase III Protocol Differences Phase IIb Double Blind Placebo Controlled Trial Phase III Double Blind Placebo Controlled Trial Up to 3 treatment cycles Up to 4 treatment cycles Modeling vs. No-modeling Modeling 3 : 1 XIAFLEX : Placebo 2 : 1 XIAFLEX : Placebo = 6 months of disease = 12
Slide 39: Phase III Studies Are at Least 85% Powered to Achieve Co-primary Endpoints
We Believe Phase III Double-blind Studies Are at Least 85% Powered to Achieve Co-primary Endpoints • Statistical significance requires greater than 27% mean net improvement from baseline in the Peyronie’s disease bother domain of the PDQ over placebo • Statistical significance requires greater than
Slide 40: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe
Slide 41: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually , > 210,000 Peyronie’s Candidates Could Exist between U.S. and Europe
Slide 42: Strategic Partnership with Pfizer for XIAFLEX in EU
Strategic Partnership with Pfizer for XIAFLEX in EU • Strong working relationship with goal to obtain EMA approval • Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. • Pfizer is primarily responsible for: European
Slide 43: Auxilium
| Auxitium rer innovations for tite
Slide 44: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market Once-a-day application *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 45: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies Total Testosterone Free Testosterone • 16 clinical studies involving approx. 1,800 patients > Largest placebo-controlled study ever conducted • Clinical trial of Testim vs. AndroGel ® > Testim provides 30% higher testosterone absorption (p<0.001)
Slide 46: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data
Slide 47: Continuing Track Record of Consistent Revenue Growth
Continuing Track Record of Consistent Revenue Growth 2Q10 TRX Y/Y Growth:
Slide 48: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are licensed from CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent No. 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use clai
Slide 49: FDA Has Granted Our Citizen's Petition In Part and Denied It In Part
FDA Has Granted Our Citizen's Petition In Part and Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers
Slide 50: FDA Recently Granted Abbott's Citizen's Petition in Part and Denied in Part
FDA Recently Granted Abbott’s Citizen’s Petition in Part and Denied in Part • Although not commenting upon any filing in particular, the FDA agreed that: – Applications for testosterone gel products with different penetration enhancers must be submitted as a 505(b)(2) NDA rather than an ANDA. – A su
Slide 51: 2010 Financial Results and 2010 Guidance
Testim Revenues $91.6 $72.1 $185-195 XIAFLEX Revenues $4.3 $1.8 N/A R&D Expense* $19.6 $27.3 $50-60 SG&A Expense* $77.3 $55.8 $160-170 Net Loss ($22.1) ($26.0) N/A Stock – Based Comp Expense (* included) $8.4 $9.4 $22-25 Cash & Cash Equivalents $165.0 2010 Financial Results and 2010 Guidance ($ Mill
Slide 52: Auxilium's Plan to Provide Visibility on XIAFLEX Launch
Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • For 3Q 2010, we anticipate that XIAFLEX net revenues will be in the range of $5.5 million to $6.5 million, including approximately $1.1 million in revenue recognized from milestones previously received under the Pfizer contract. • We will con
Slide 53: Strategic Priorities in 2010
Strategic Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EU Dupuytren’s submission and prepare for their eventual launch; • Rapidly enroll Peyronie’s disease phase III clinical program • Projected d
Auxilium Pharmaceuticals — Investor Presentation (October 2010) on 6ix